The exponential imperative: Rethinking biopharma strategy for a non

The exponential imperative: Rethinking biopharma strategy for a non

This article – Part 1 of a two-part series – is a call to rethink biopharma strategy from the ground up. We’ll explore why legacy approaches fail, unpack how megatrends are rewriting the rules, and challenge leaders to rethink how we position, choose, execute, and govern in an exponential world.